KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Ruxolitinib as the first post-steroid treatment for acute and chronic graft-versus-host disease.

Mattia Algeri, Marco Becilli, Franco Locatelli

Expert Rev Clin Immunol 19(11) 1299-1313

PMID37606511
PMCID-
DOI10.1080/1744666X.2023.2249230
发表日期2023-08-22
摘要

摘要

INTRODUCTION: Acute and chronic graft-versus-host disease (GvHD) are potentially life-threatening complications occurring after allogeneic stem cell transplantation (allo-HSCT). Although steroids represent the first-line treatment for both conditions, in those patients who do not adequately benefit from steroid therapy, standardized treatment algorithms are lacking. In recent years, ruxolitinib has emerged as the most promising agent for the second-line therapy of steroid-refractory (SR)-GvHD. AREAS COVERED: This review will summarize the biological properties and the mechanistic aspects that justify the therapeutic role of ruxolitinib in GvHD. In addition, current treatment options for SR-GvHD will be briefly discussed. Finally, results of the most relevant clinical trials on the use of ruxolitinib for SR-GvHD will be analyzed, with a particular focus on two phase-III randomized trials in which ruxolitinib demonstrated its superiority in comparison with the best available therapy. EXPERT OPINION: Ruxolitinib has considerably improved the outcome of patients with SR-acute/chronic-GvHD and should be regarded as the standard-of-care option when corticosteroids fail or cannot be tapered. Nevertheless, a number of questions still remain unanswered and significant room for improvement exists. Additional observations derived from a longer follow-up will certainly increase our expertise in the management of this powerful therapy.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。